1988810334497112064

mRNA & LNP Delivery Insights

Non-Viral CAR-T Therapy: Why In Vivo CAR-T Is Emerging as an Alternative to Viral Delivery

Non-Viral CAR-T Therapy: Why In Vivo CAR-T Is Emerging as an Alternative to Viral Delivery

Explore how non-viral in vivo CAR-T uses targeted lipid nanoparticles to program T cells directly, and how it compares with conventional viral CAR-T delivery.

mRNA & LNP Delivery Insights

Jul 15,2026

LNP Delivery for CRISPR Gene Editing: How to Choose the Right Delivery Strategy

LNP Delivery for CRISPR Gene Editing: How to Choose the Right Delivery Strategy

Learn how LNP delivery supports CRISPR gene editing, including Cas9 mRNA and sgRNA delivery, non-viral delivery strategies, formulation challenges, and applications in CAR-T, T cell engineering, cancer research, and liver gene editing.

mRNA & LNP Delivery Insights

Jul 06,2026

What Is Targeted LNP Delivery and Why It Matters for mRNA Therapeutics

What Is Targeted LNP Delivery and Why It Matters for mRNA Therapeutics

mRNA therapeutics have opened new possibilities in vaccines, cancer immunotherapy, protein replacement, gene editing, and rare disease treatment. Unlike traditional drugs, mRNA does not need to enter the nucleus or alter the genome. Instead, it provides cells with temporary instructions to produce a therapeutic or functional protein. However, mRNA is fragile, negatively charged, and easily degraded by nucleases. It also cannot efficiently cross cell membranes on its own. This is why delivery technology is critical to the success of mRNA therapeutics.

mRNA & LNP Delivery Insights

Apr 28,2026

mRNA Delivery for CAR-T Therapy: From Concept to In Vivo Application

mRNA Delivery for CAR-T Therapy: From Concept to In Vivo Application

mRNA delivery is emerging as a promising strategy for advancing CAR-T therapy beyond traditional ex vivo manufacturing. Compared with conventional viral-based approaches, mRNA enables flexible, non-integrating, and potentially faster cell engineering. However, efficient in vivo delivery to T cells remains a major challenge due to poor cellular uptake, off-target distribution, and delivery barriers. This article outlines the transition from CAR-T concept to in vivo application, reviews current delivery limitations, and highlights why targeted lipid nanoparticles (tLNPs) are becoming an important solution for next-generation CAR-T research and development.

mRNA & LNP Delivery Insights

Apr 14,2026

How to Deliver mRNA to T Cells In Vivo: Challenges and Solutions

How to Deliver mRNA to T Cells In Vivo: Challenges and Solutions

Delivering mRNA to T cells in vivo is a major challenge in next-generation cell therapy development. This article explores why T cells are difficult targets for systemic mRNA delivery, reviews current delivery approaches and their limitations, and highlights the potential of targeted lipid nanoparticles (tLNPs) as a non-viral solution for in vivo CAR-T applications. It also discusses how targeted mRNA delivery strategies may help improve precision, safety, and scalability in therapeutic research.

mRNA & LNP Delivery Insights

Apr 03,2026

< 1 >